Hageman factor, high molecular weight kininogen, and prekallikrein in chronic liver disease

C CORDOVA, F VIOLI, C ALESSANDRI, D FERRO, M SALIOLA, F BALSANO

From the Institute of Clinical Medicine I, University of Rome "La Sapienza", Italy

SUMMARY The activities of Hageman factor, high molecular weight kininogen (HMWK), and prekallikrein were studied in patients who had chronic active hepatitis and cirrhosis. Serum HMWK and prekallikrein activities were decreased in chronic active hepatitis and cirrhosis, but Hageman factor activity was low in cirrhosis only. The reduction of prekallikrein, HMWK, and Hageman factor was dependent on the degree of liver failure. Similar prekallikrein values were found in serum samples, activated or not, with an excess of Hageman factor and HMWK, which suggests that the decrease of prekallikrein in liver disease is not influenced by the simultaneous decrease of Hageman factor and HMWK.

Prekallikrein, a protein synthesised by liver cells, is an activator of intrinsic coagulation and fibrinolytic pathways. A recent investigation showed that prekallikrein plasma activity is a very sensitive marker of liver failure, making it a potentially useful indicator of liver insufficiency.

The functional assay of prekallikrein requires Hageman factor and high molecular weight kininogen (HMWK), two constituents of the initial coagulation phase that can be reduced in liver failure. In fact, at least 25% of normal Hageman factor activity is necessary for prekallikrein to be converted into kallikrein; HMWK seems to be a cofactor in the initial rate of kallikrein formation. As low values of prekallikrein in patients with cirrhosis could be due to low Hageman factor and HMWK activities, we studied the relation between prekallikrein, Hageman factor and HMWK in patients affected by chronic liver disease to evaluate the in vitro influence of Hageman factor and HMWK on prekallikrein activation. Analysis of prekallikrein activity was performed with and without a clotting activator containing an excess of Hageman factor and HMWK.

Material and methods

The study was carried out on 30 patients with chronic liver disease: 10 had chronic active hepatitis (six men, four women; aged 27–58 years); and 20 had cirrhosis (13 men, seven women; aged 32–73 years). Chronic active hepatitis was diagnosed by needle liver biopsy, according to the recommendations of the International Committee. Cirrhosis was diagnosed by liver biopsy in 11 patients and on clinical data and laboratory tests in nine patients. These included the following criteria: hepatosplenomegaly; ascites or jaundice, or both; spider naevi; signs of liver failure (low concentrations of serum albumin and vitamin K dependent factors) and an increase of aminotransferases and the gamma band in serum protein electrophoretic patterns. Liver needle biopsy was not performed in these nine patients as their serum biochemistry was severely abnormal and the biopsy risks were too high. Patients were considered to be decompensated if they showed at least two of the following signs: ascites; hepatic encephalopathy; prothrombin test (Quick) < 40%; serum albumin < 30 g/l; serum bilirubin > 68.4 µmol/l. Nineteen patients (seven with chronic active hepatitis and 12 with cirrhosis) had antibodies for hepatitis B virus; eight with cirrhosis had clinical histories of alcoholism, and three patients were thought to be affected by autoimmune chronic active hepatitis. All studies were made with the patients’ informed consent in accordance with the Helsinki Declaration.

Coagulation study

Blood samples were taken from fasting subjects, mixed with 0.13 mol/l sodium citrate in a ratio of 9:1, and centrifuged for 15 minutes at 2000 g.
Prothrombin activity was performed by Normotest (Nyegaard and Co), according to the manufacturer’s instructions. Schnitger and Gross coagulometer was used for evaluating Normotest.

The prekallikrein activity was comprised 100 μl diluted plasma (50 μl plasma plus 600 μl 50 mM Tris buffer, pH 7.8), 800 μl diluted Cephotest (nine parts Tris buffer plus one part Cephotest; Nyegaard and Co), or 800 μl diluted prekallikrein activator (nine parts Tris buffer plus one part prekallikrein activator, a mixture of ellagic acid, cephalin, and plasma containing Hageman factor and HMWK (Kabi Diagnostics), which were incubated for three minutes at 37°C and then added to 0·6 mM substrate S-2302 (Kabi Diagnostics). The reaction mixture was incubated at 37°C and stopped after one minute with 50% acetic acid. Prekallikrein activity was read at 405 nm on a Beckman spectrophotometer and calculated by a standard curve performed by scaled dilution of normal pooled plasma.

Plasma activities of Hageman factor and HMWK were assessed by a modification of a prothrombin time using plasma congenitally deficient in Hageman factor (Boehringer Biochimia) and HMWK (Nyegaard and Co) plasma. Clotting time was measured with a Schnitger and Gross coagulometer, and the percentage activities of Hageman factor and HMWK were calculated from a calibration curve performed as above.

Twenty healthy subjects matched for age were studied as controls. The mean and SD of the results and Student’s t test were calculated.

### Table 1

<table>
<thead>
<tr>
<th></th>
<th>Healthy subjects</th>
<th>Chronic active hepatitis</th>
<th>Liver cirrhosis</th>
<th>Compensated liver cirrhosis</th>
<th>Decompensated liver cirrhosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normotest</td>
<td>91·5 (7·5)</td>
<td>66 (16·9)†</td>
<td>39·6 (15·3)‡</td>
<td>49·4 (15·2)</td>
<td>25·6 (5·6)‡</td>
</tr>
<tr>
<td>Prekallikrein</td>
<td>91·6 (12·5)</td>
<td>62 (17·9)‡</td>
<td>32·0 (20·3)‡</td>
<td>42·8 (12·6)</td>
<td>16·7 (7·8)‡</td>
</tr>
<tr>
<td>High molecular</td>
<td>96 (19)</td>
<td>80 (27)</td>
<td>42 (11)‡</td>
<td>50·4 (10·3)</td>
<td>32·8 (3·8)‡</td>
</tr>
<tr>
<td>weight kininogen</td>
<td>108 (16)</td>
<td>88 (19)*</td>
<td>52 (12)‡</td>
<td>60·2 (11·9)</td>
<td>44·6 (6)‡</td>
</tr>
</tbody>
</table>

*p < 0·025; †p < 0·01; ‡p < 0·001.

### Results

Low values of prekallikrein and HMWK were observed in chronic active hepatitis, while Hageman factor activity was within the normal range (table 1). Decreased values of prekallikrein and HMWK and low Hageman factor activity were seen in cirrhosis, where the amount by which these proteins were decreased was related to the degree of liver failure. In fact, decompensated patients with cirrhosis had lower prekallikrein, Hageman factor, and HMWK values than did compensated patients. Similar prekallikrein values were observed independent of whether or not the clotting activator contained Hageman factor and HMWK (table 2). This was also evident in decompensated patients with cirrhosis who had very low prekallikrein values. In this subgroup the lowest Hageman factor and HMWK values were 27% and 39%, respectively.

### Discussion

Previous investigations have shown that prekallikrein plasma activity is decreased in patients with chronic liver disease, depending on the degree of liver failure. Prekallikrein values were correlated with those of Normotest, which determines vitamin K dependent factor activity and is considered to be a good marker of liver failure. A more recent investigation suggested that prekallikrein could be a good prognostic indicator of liver failure as prekallikrein values of patients who had not survived with cirrhosis were

### Table 2

<table>
<thead>
<tr>
<th></th>
<th>Chronic active hepatitis</th>
<th>Compensated liver cirrhosis</th>
<th>Decompensated liver cirrhosis</th>
<th>Liver cirrhosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prekallikrein</td>
<td>62 (17·9)</td>
<td>42·8 (12·6)</td>
<td>16·7 (7·8)</td>
<td>32 (20)</td>
</tr>
<tr>
<td>Prekallikrein +</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>activator</td>
<td>61 (16) ns</td>
<td>42·3 (13·8) ns</td>
<td>18·2 (7·6) ns</td>
<td>32 (18) ns</td>
</tr>
</tbody>
</table>
appreciably lower than those of survivors. This agrees with a previous finding that prekallikrein plasma activity reflects residual functional liver cell mass. Very low prekallikrein values, however, such as those observed in decompensated cirrhosis could be due to a concomitant lowering of Hageman factor or HMWK, or both, two proteins active in the initial phase of the intrinsic coagulation pathway that are necessary for in vitro prekallikrein activation. Hageman factor and HMWF activities are reduced in chronic liver disease, but not so low as to affect prekallikrein assay; and this is supported by finding similar prekallikrein values independently of whether or not the prekallikrein activator contained an excess of Hageman factor and HMWF.

The obvious conclusion of this study is that in cirrhosis, particularly in decompensated cirrhosis, where the lowest Hageman factor and HMWF values can be found, prekallikrein activity does not seem to be influenced by Hageman factor and HMWF activity values. This is probably due to the limited reduction of Hageman factor and HMWF, which never reach values below 25%. The low plasma activity of prekallikrein found in decompensated cirrhosis should, therefore, be regarded as a direct consequence of liver protein synthesis failure, provided that other conditions known to affect prekallikrein activity, such as endotoxaemia or intravascular coagulopathy, are excluded.

References


Requests for reprints to: Professor F Violi, Institute of Clinical Medicine I, University of Rome "La Sapienza", Policlinico Umberto I, 00161 Rome, Italy.